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Abstract
Background
Few data are available on the virological and clinical outcomes of advanced liver disease
patients retreated after first-line DAA failure.
Aim
To evaluate DAA failure incidence and the retreatment clinical impact in patients treated in
the advanced liver disease stage.
Methods
Data on HCV genotype, liver disease severity, and first and second line DAA regimens were
prospectively collected in consecutive patients who reached the 12-week post-treatment
and retreatment evaluations from January 2015 to December 2016 in 23 of the PITER net-
work centers.
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Results
Among 3,830 patients with advanced fibrosis (F3) or cirrhosis, 139 (3.6%) failed to achieve
SVR. Genotype 3, bilirubin levels >1.5mg/dl, platelet count <120,000/mm3 and the sofosbu-
vir+ribavirin regimen were independent predictors of failure by logistic regression analysis.
The failure rate was 7.6% for patients treated with regimens that are no longer recom-
mended or considered suboptimal (sofosbuvir+ribavirin or simeprevir+sofosbuvir±ribavirin),
whereas 1.4% for regimens containing sofosbuvir combined with daclatasvir or ledipasvir or
other DAAs. Of the patients who failed to achieve SVR, 72 (51.8%) were retreated with a
second DAA regimen, specifically 38 (52.7%) with sofosbuvir+daclatasvir, 27 (37.5%) with
sofosbuvir+ledipasvir, and 7 (9.7%) with other DAAs ±ribavirin. Among these, 69 (96%)
patients achieved SVR12 and 3 (4%) failed. During a median time of 6 months (range: 5–14
months) between failure and the second DAA therapy, the Child-Pugh class worsened in 12
(16.7%) patients: from A to B in 10 patients (19.6%) and from B to C in 2 patients (10.5%),
whereas it did not change in the remaining 60 patients. Following the retreatment SVR12
(median time of 6 months; range: 3–12 months), the Child-Pugh class improved in 17
(23.6%) patients: from B to A in 14 (19.4%) patients, from C to A in 1 patient (1.4%) and
from C to B in 2 (2.9%) patients; it remained unchanged in 53 patients (73.6%) and wors-
ened in 2 (2.8%) patients. Of patients who were retreated, 3 (4%) had undergone OLT
before retreatment (all reached SVR12 following retreatment) and 2 (2.8%) underwent OLT
after having achieved retreatment SVR12. Two (70%) of the 3 patients who failed to achieve
SVR12 after retreatment, and 2 (2.8%) of the 69 patients who achieved retreatment SVR12
died from liver failure (Child-Pugh class deteriorated from B to C) or HCC complications.
Conclusions
Failure rate following the first DAA regimen in patients with advanced disease is similar to or
lower than that reported in clinical trials, although the majority of patients were treated with
suboptimal regimens. Interim findings showed that worsening of liver function after failure, in
terms of Child Pugh class deterioration, was improved by successful retreatment in about
one third of retreated patients within a short follow-up period; however, in some advanced
liver disease patients, clinical outcomes (Child Pugh class, HCC development, liver failure
and death) were independent of viral eradication.
Introduction
An estimated 71 million people worldwide are chronically infected with the hepatitis C virus
(HCV) [1]. Chronic HCV infection places a large burden on health systems because it is one of
the leading causes of cirrhosis, hepatocellular carcinoma (HCC) and orthotropic liver trans-
plantation (OLT) [2,3]. Following the introduction of therapy with interferon (IFN)-free
Direct Acting Antivirals (DAAs), the World Health Organization (WHO) set the goal of
reducing liver-related deaths by 65% by the year 2030 [4].
For HCV therapy to be considered successful, its use should result in viral clearance with a
sustained virologic response (SVR), as well as improved clinical outcomes. Following IFN-
based treatment, SVR has been found to be associated with improved overall clinical outcomes
[5,6]. In patients with compensated HCV-related cirrhosis, SVR was associated with slower
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disease progression, fewer liver-related mortalities, and the survival rate is similar to that of the
general population [7–9]. Marked improvements in clinical outcomes following SVR have also
been reported in patients with severe liver damage [10–12].
The universal treatment of all HCV-infected individuals has been hampered by the high
cost of DAAs, which makes difficult for the payers to sustain their use. From January 2015 to
March 2017, the Italian Medicines Agency limited the use of DAA to patients with advanced
and progressive liver disease and to a few other categories of patients [13].
DAAs are highly effective, well tolerated and can be administered even in patients with
advanced liver disease. However, the failure to eradicate HCV RNA with DAAs remains an
important challenge mainly in this subset of patients [14]. The objective of the present analysis
was to estimate the incidence of DAA failure and the clinical impact of retreatment in a real-
life cohort of patients with advanced fibrosis/cirrhosis.
Patients and methods
Patients
The study was prospective in design and was conducted among patients attending 23 clinical
centers involved in PITER (Italian Platform for the Study of Therapies for Viral Hepatitis)
[15]. For the purpose of the present study, we retrieved all consecutive patients treated with
DAA who reached the 12-week post-treatment HCV RNA evaluation from January 2015 to
June 2016. The study population included patients eligible for DAA according to the indica-
tions of the Italian Medicines Agency, which limit use mainly to patients with advanced and
progressive liver disease (i.e., fibrosis stage of F3 or higher), patients with severe extrahepatic
HCV manifestations and patients who had undergone orthotropic liver transplantation
(OLT), independently of the liver disease stage [13–16].
The DAAs available in Italy from January to May 2015 were sofosbuvir (SOF) and simepre-
vir (SIM), whereas since June 2015, daclatasvir and the fixed dose combinations ledipasvir
(LDV)/SOF and ombitasvir/paritaprevir /ritonavir+dasabuvir (3D regimen) have also been
available.
Data were collected on the HCV genotype, the liver disease stage and the DAA regimen
used. Patients enrolled in clinical trials were excluded from the study. SVR was defined as
being HCV-RNA-negative at the end of treatment and at the 12-week post-treatment evalua-
tion. SVR was defined as undetectable HCV-RNA level as assessed by highly sensitive molecu-
lar methods (lower limit of detection ranging from < = 12 to< = 15 IU/ml), 12 weeks after
completion of anti HCV therapy. This is referred to as the SVR12 and achieving an SVR12 is
the goal of therapy. The fibrosis stage was defined based on liver transient elastography data,
which were considered as validated if each patient had at least 10 valid stiffness measurements,
with a success rate of at least 80%, an interquartile range of less than 30% of the median stiff-
ness score, and a Body Mass Index of<30kg/m2. F3 fibrosis stage was classified if the stiffness
score was within the range of 9.5–12.5 kPa. Liver disease was classified as “progressive/severe
liver disease” if the stiffness score was equal to or higher than 12.5 kPa or if there were signs of
liver cirrhosis (signs of portal hypertension) [17,18]. The diagnosis of cirrhosis was based on
liver biopsy data or either transient elastography or a combination of clinical, laboratory and
imaging findings.
The overall duration of the observation included the period from January 2015 to Decem-
ber 2016 (end of the period for SVR12 evaluation for patients who were retreated with a sec-
ond DAA regimen during the period from January 2015 to June 2016). The following clinical
data were collected at baseline following the first and second treatment and at the end of the
follow-up of the second treatment: liver fibrosis stage and/or presence of clinical cirrhosis,
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Child-Pugh score and complications of severe liver disease, if present (i.e., ascites, encephalop-
athy, spontaneous bacterial peritonitis, esophageal varices, bleeding from esophageal varices,
and HCC development). Patients underwent semiannual US surveillance, and the diagnosis of
HCC was based on international guidelines [19]. Data were also collected on OLT and previ-
ous IFN treatment.
Statistical analysis
Differences among the proportions were evaluated by chi-square or Fisher test, as appropriate,
whereas the Student test was used for continuous variables. A P-value of less than 0.05 was
considered as significant.
The crude odds ratios (ORs) that link HCV treatment failure to potential risk factors (age,
gender, previous IFN-based treatment, HCV RNA genotype, presence of cirrhosis versus F3
fibrosis stage, bilirubin levels, platelets count, and DAA treatment regimens) were calculated
by univariate analysis. Adjusted ORs were calculated by multiple logistic regression analysis to
identify variables that were independently associated with failure. The reference category for
OR estimates was that of the most favorable levels of exposure. HCC incidence was reported as
de novo HCC in patients without the HCC diagnosis at baseline, prior to start of treatment.
Ethics
The study was conducted in accordance with the guidelines of the Declaration of Helsinki and
the principles of Good Clinical Practice. The study protocol was approved by the Ethic Com-
mittee of Istituto Superiore di Sanità (Italian National Institute of Public Health) and by the
local Ethics Committees of each clinical center. The patients’ data were evaluated through an
anonymous analysis, adopting codes generated by the electronic case-report form. Informed
consent had been obtained from each patient participating in this study.
Results
Patient characteristics at the first DAA treatment, by genotype and DAA
regimen
From January 2015 to June 2016, 3,869 consecutive patients underwent IFN-free DAA treat-
ment. Of these patients, 3,691 (95.3%) reached the SVR12, 139 (3.6%) did not achieve the
SVR12, and 39 (1.1%) did not complete the 12-week post-treatment evaluation. The baseline
characteristics of the patients who completed the DAA treatment according to the response to
treatment are reported in Table 1. No differences were observed between those who reached
SVR12 and those who did not in terms of age, gender, liver function tests (transaminase levels)
and Meld score, whereas HCV RNA genotype 3, Child Pugh class B/C, bilirubin levels higher
than 1.5 mg/dl and platelets count equal or less than 120,000/mm3 were significantly more rep-
resented among non-responders. SOF+ribavirin (RBV) compared to the use of 2DAAs combi-
nation regimens, was more frequently used among non-responders. According to the logistic
regression analysis, an independent association was found between treatment failure and older
age, genotype 3 (OR 1.9; 95% CI: 1.1–3.5), bilirubin levels higher than 1.5 mg/dl (OR 1.8; 95%
CI: 1.1–3.4), platelet count lower than 120,000/mm3 (OR 1.9; 95% CI: 1.1-3-4) and SOF+ RBV
regimen (OR 2.6; 95% CI: 1.6–4.3) (Table 2).
Failure rates following the first DAA regimen, according to HCV genotype and treatment
regimen are reported in Table 3. The highest failure rate (9.6%) was observed for patients
treated with SOF+RBV, for all genotypes except genotype 2, for which the failure rate was low
(1.6%). The failure rate for SOF+SIM ±RBV, when used for genotypes 1 and 4, for which it
Failure to HCV Direct Acting Antivirals
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Table 1. Characteristics of the study patients according to SVR following the first DAA treatment.
Variables N. of patients
Failure
139 (%)
N. of patients
SVR12
3,691 (%)
P value
Age 58 years (range: 34–85) 59 years (range: 34–84) 0.1
Female/Male 31 (22.3) 993 (26.9) 0.2
Male 108 (77.6) 2,698 (73.1)
IFN experienced 63 (45.3) 1,801 (48.7) 0.4
Naive 76 (54.7) 1,890 (51.2)
Genotypes 1 80 (57.6) 2,622 (71.0) <0.001
Genotype 2 9 (6.4) 547 (14.8)
Genotype 4/5 12 (8.6) 182 (4.9)
Genotype 3 38 (27.3) 340 (9.2)
F3 Fibrosis stage 17 (12.2) 658 (17.8) 0.02
F4/Cirrhosis
Child Pugh Class A
86 (61.2) 2945 (79,8)
F4/Cirrhosis
Child Pugh Class B/C
36 (25.8) 746 (20.2)
Bilirubin levels1.5 mg/dl 103 (74.1) 3,215 (87.1) <0.001
Bilirubin levels >1.5 mg/dl 36 (25.8) 476 (12.9)
Platelets count >120,000/mm3 63 (45.3) 2,190 (59.3) <0.001
Platelets count120,000/ mm3 76 (54.7) 1,501 (40.6)
Median Meld score (Range) 9.7 (6–20) 9.2 (6–18) 0.3
Median Alanine Aminotransferase Levels U/l (Range) 66 (49–120) 57 (43–134) 0.2
Median Aspartate Aminotransferase Levels U/l (Range) 72 (49–102) 68 (55–98) 0.2
2DAA±RBV treatment 71 (51.1) 3,049 (83) <0.001
SOF/RBV treatment 68 (48.9) 642 (17)
https://doi.org/10.1371/journal.pone.0185728.t001
Table 2. Univariate and logistic regression analysis linking failure with independent variables.
Variables Crude OR
95% CI
Adjusted OR
95% CI
Age 0.97 (0.95–0.99) 0.97 (0.94–0.98)
Female 0
Male 1.7 (0.9–2.6) 1.3 (0.8–2.2)
IFN experienced 0
Naive 1 (0.68–1.46) 1.5 (0.9–2.2)
Genotypes 1 0
Genotype 2
Genotype 4/5
Genotype 3 3.4 (2.2–5.4) 1.9 (1.1–3.5)
F3 Fibrosis stage 0
F4/Cirrhosis 1.79 (0.9–3.4) 1.25 (0.6–2.5)
Bilirubin levels1.5 0
Bilirubin levels >1.5 2.08 (1.4–3.06) 1.8 (1.1–3.4)
Platelets count >120,000 0
Platelets count120,000 1.68 (1.2–2.4) 1.9 (1.1–3.4)
2DAA±RBV treatment 0
SOF/RBV treatment 2.5 (1.8–3.6) 2.6 (1.6–4.3)
https://doi.org/10.1371/journal.pone.0185728.t002
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was recommended, was 5.2%. Overall, the failure rate of the regimens that are no longer rec-
ommended (SOF+RBV) and those considered to be suboptimal (SOF/SIM±RBV), was 7.6%
(106/1,393 patients), whereas for the regimens that are currently deemed appropriate, it was
1.4% (33/2,437 patients). In IFN-experienced patients, RBV was used and/or treatment was
extended from 12 to 24 weeks, as recommended by guidelines. Only in 2 (1.4%) of the 140
patients (IFN-naïve, genotype 3, with cirrhosis), the use of SOF+DCV for 24 weeks was not
associated with the use of RBV, as recommended. Lastly, a high failure rate (50–100%) was
recorded in a few patients with HCV genotypes 2, 3 and 5, who received inappropriate treat-
ment with SOF+SIM±RBV.
Second DAA regimen following failure
After a median time of 6 months (range: 5–14 months) from the first treatment failure, 72
(51.8%) of the 139 patients who failed to achieve the SVR12 were treated with a second DAA
regimen, with or without RBV, with treatment lasting 24 weeks, as recommended by the most
recent guidelines of the European Association for the Study of the Liver (EASL) [19]. All the
72 retreated patients had liver cirrhosis. The second DAA regimen consisted of: i) SOF/DCV
in 38 patients (52.8%) (of whom 23, who had either genotype 1a or 3, also received RBV), ii)
SOF/LDV in 27 patients (37.5%) (of whom 13, who had either genotype 1a or 4, received
RBV), or iii) other DAA regimens in 7 patients (9.7%), as shown in Table 4.
Overall, the SVR was achieved in 69 (95.8%) of the 72 patients. Among the 38 patients treated
with SOF/DCV, 36 (94.7%) achieved SVR12 and 2 (5.3%) had treatment failure (one with geno-
type 1 and one with genotype 3). Of the 27 patients treated with SOF/LDV, 26 (96.3%) achieved
SVR12, and 1 (3.7%) experienced treatment failure (genotype 1a). The few patients retreated with
other regimens, as reported in Table 4, did not show failure following retreatment.
Modifications of liver disease stage following DAA failure and
retreatment
Fig 1A shows the modifications in disease severity in the 72 patients who had cirrhosis and
were retreated. Following treatment failure to retreatment (median time 6 months; range:
Table 3. Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treat-
ment evaluation (n = 3,830 patients).
Overall HCV genotype
N. of failures/N. of treated patients (%)
DAA regimen N. of failures/N. of treated patients (%) 1a 1b 2 3 4 5
139/3830 (3.6)
SOF+RBV 68/710
(9.6)
5/15
(33.3)
20/56
(35.7)
8/499
(1.6)
32/132
(24.2)
3/8
(37.5)
-
SOF+SIM±RBV 38/683
(5.6)
8/99
(8)
24/520
(4.6)
1/2
(50)
1/1
(100)
3/60
(5)
1/1
(100)
SOF+LDV±RBV 16/1002
(1.6)
3/200
(1.5)
10/752
(1.3)
- 0/1
(0)
3/44
(6.8)
0/5
(0)
3D±RBV 9/894
(1)
3/86
(3.5)
6/806
(0.7)
- - 0/2
0
-
2D+RBV 2/64
(3.1)
- - - - 2/59
3.4%
0/5
(0)
SOF+DCV±RBV 6/471
(1.3)
0/47
0
1/115
(0.9)
0/55
(0)
5/244
(2)
0/10
(0)
SIM+DCV 0/6
(0)
- 0/6
(0)
- - - -
https://doi.org/10.1371/journal.pone.0185728.t003
Failure to HCV Direct Acting Antivirals
PLOS ONE | https://doi.org/10.1371/journal.pone.0185728 October 4, 2017 6 / 13
5–14 months), the Child-Pugh class worsened in 12 (16.7%) patients from A to B in 10 patients
(19.6%) and from B to C in 2 patients (10.5%), whereas it remained unchanged in the remain-
ing 60 patients. Following the retreatment SVR12 to the end of the study (median time of 6
months; range: 3–12 months), the Child-Pugh class improved in 17 (23.6%) patients: from B
to A in 14 (19.4%) patients, from C to A in 1 patient (1.4%) and from C to B in 2 (2.9%)
patients; it remained unchanged in 53 patients (73.6%) and worsened in 2 (2.8%) patients.
Following the first DAA failure, in patients with an increase in the Child-Pugh class, the
mean MELD score pre-treatment was 9 (range: 7–13) and post-treatment failure was 12
(range: 9–15) (p<0.05). In patients in whom the Child-Pugh class was unmodified after failure,
the mean pre- and post-treatment MELD score was 8 (range: 6–9) in Child-Pugh class A
patients, while in Child-Pugh B class patients the pre-treatment MELD score was 12 (range:
9–21) and the post-treatment score was 13 (range: 9–17) (p = 0.03). Following the retreatment
SVR, in Child-Pugh class B patients with a MELD score >12, the median MELD score signifi-
cantly improved from 15 to 10 (P<0.001), whereas it did not change in the remaining retreated
patients.
Both ascites and encephalopathy showed a numerical increase after treatment failure, fol-
lowed by a decrease after SVR12, although the numbers were too small to allow for a meaning-
ful statistical comparison (data not shown). No variceal bleeding or episodes of Spontaneous
Bacterial Peritonitis occurred during the study period. Of the 72 patients who were retreated, 3
(4%) had undergone OLT before retreatment, for liver failure and/or they had developed HCC
(all reached SVR12 following retreatment) and 2 (2.8%) underwent OLT after having achieved
retreatment SVR12 (one in Child-Pugh class B cirrhosis and one for HCC development). Two
(70%) of the 3 patients who also failed to achieve SVR12 after retreatment, and 2 (2.8%) of the
69 patients who achieved retreatment SVR12 died from liver failure complications (Child-
Pugh class deteriorated from B to C) or from HCC.
Of 67 (4%) patients who were awaiting retreatment following the study period (median
time of follow-up 6 months: range 5.3–12.4 months), 50 had liver cirrhosis, 35 in Child Pugh
A class and 15 in Child Pugh B class. Of 35 patients in Child Pugh A class 4 (11.4%) worsened
in Child Pugh B class during the study period whereas the remaining did not change it (Fig
Table 4. Patients who received a second DAA treatment, by type of first regimen and HCV genotype (n = 72 patients).
Second DAA Regimen
First DAA Regimen SOF+DCV
Number of patients (%)
SOF+LDV
Number of patients (%)
Other Regimens
N. patients
38
(52.7%)
Gt1 Gt2 Gt3 Gt4 N. patients
27
(37.5%)
Gt1 Gt3 Gt4 N. patients
7
(9.7%)
Gt1, Gt3, Gt4
SOF+RBV 29 7* (24.1) 3 (10.3) 19* (65.5) 14 11 (78.6) 1(7.1) 2(14.2) 1 PEG+SOF+RBV
(Gt3)
SOF+SMV 9 7 (77.8) - - 2 (22.2) 13 13* (100) 2 3D (Gt1);
2D (Gt4)
SOF+LDV - - - - - - - - - 4 3D; (Gt1)
SOF+SIM
(Gt1 and Gt4)
SVR12 36
(94.7)
13 (92.8) 3
(100)
18
(94.7)
2
(100)
26
(96.3)
23
(95.8)
1
(100)
2
(100)
8
(100)
*1 patient Gt1 and 1 patient Gt3 did not achieved the SVR12 to the retreatment with SOF+DCV; 1 patient Gt1 did not achieved the SVR12 to the
retreatment with SOF+LDV
https://doi.org/10.1371/journal.pone.0185728.t004
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1B). Pre-treatment Meld score was 8 (range: 6–17) whereas during the awaiting treatment fol-
low up period (until the end of the study) it was 9.2 (range: 7–17) (p = 0.2).
Of patients who achieved the SVR following the first line DAA therapy an interim analysis of
short time clinical outcomes was available for 481 patients with liver cirrhosis who had at least
more than 3-month follow-up (median follow-up 5.5 months: range 3.8–9.4 months) following
SVR. Among them, in the 76 Child-Pugh class B patients the classification improved to Child-
Pugh A in 56 patients (74%), while in 345 Child-Pugh class A patients, the classification remained
stable in 323 patients (94%) and worsened to Child-Pugh B in 22 patients (6%) (Fig 1C).
HCC incidence
Following treatment failure, de novo HCC was observed in 16 (13.8%) of the 116 patients with
cirrhosis, free of HCC at baseline (6 of 122 patients with liver cirrhosis in whom HCC was
present prior to the start of first DAA treatment were excluded by this analysis). In particular,
it was diagnosed at the end of treatment (or 1 month after the end of treatment) in 6 patients
(37.5%) and during a median follow-up of 6 months (range: 3–11 months) in 10 patients
(62.5%). At the retreatment SVR12, HCC was diagnosed in 4 of the 56 patients (7.1%) free of
HCC at start of the retreatment.
Fig 1. Modifications of liver disease stage following DAA treatment in patients with cirrhosis. (A) Baseline, post-failure and
post-retreatment SVR12 changes of Child Pugh Class; (B) baseline and post-failure changes of Child Pugh Class for patients who
were not retreated yet; (C) baseline and post-SVR12 changes of Child Pugh Class for patients who achieved SVR12 following the first
DAA treatment. Bold arrows indicate patients who did not change the Child Pugh Class. Dashed arrows indicate patients who
worsened the Child Pugh Class, whereas the grey arrows indicate patients who improved the Child Pugh class. In the curly brackets
are reported the number of patients for specific changes observed in the Child Pugh classes in the three points of evaluation.
n = number of patients.
https://doi.org/10.1371/journal.pone.0185728.g001
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Discussion
The overall failure rate for DAA in a large, consecutive series of HCV patients with advanced
liver disease in this multicenter, real-life study was 3.6%, which is similar to or even lower than
rates reported by clinical trials [20,21,22]. The low failure rate was achieved despite the fact
that regimens containing SOF+RBV and SOF/SIM, which are no longer recommended, were
used in 1,393 patients (36.4%), given that they were the only regimens available at the time.
The results of this study indicate that SOF/RBV treatment, genotype 3, and the severity of liver
disease (as indicated by high bilirubin levels and low platelet counts) are significantly associ-
ated to failure. The length of DAA treatment and the use of ribavirin for each patient were
applied in accordance with European Association for the Study of the Liver recommendations,
which could be one of the main reasons for the low relapse rate, despite the use of regimens
that are no longer recommended or suboptimal in this subset of difficult to treat patients.
Although sofosbuvir is a highly potent inhibitor of the NS5B polymerase, with a high
potency and a high barrier to resistance, its use as DAA monotherapy in combination with
ribavirin is currently not recommended [20–22]. This treatment regimen was mainly used
until mid-2015 because it was the only option available for patients infected with HCV geno-
type 2 or 3 [16]. The results of our study strongly confirm the high failure rate following the
use sofosbuvir as DAA monotherapy in all but HCV genotype 2 infected patients. The low fail-
ure rate observed in this study in patients infected by HCV genotype 2 was possibly because of
the treatment duration (16–24 weeks in most of the patients). In accordance with the scientific
guidelines of the American Association for the Study of Liver Diseases, the European Associa-
tion for the Study of the Liver and the Asian Pacific Association for the Study of the Liver the
use of at least 2 DAAs has significantly decreased the failure rate in all genotypes, as clearly
indicated by the results of this study [20–22]. SOF/SIM was the first regimen available follow-
ing SOF/RBV, which explains its wide use in this population. Our data confirm that the failure
rate of SOF/SIM was significantly lower than SOF/RBV for genotypes 1 and 4. Interestingly,
SOF/SIM showed a failure rate similar to that for SOF/LDV when used for genotype 4, whereas
this did not hold true for genotype 1 (SOF/SIM vs. SOF/LDV vs. SOF/DCV: 5.2% vs 1.4% vs
0.6%, respectively; P<0.001). In fact, we observed that when new DAA regimens became avail-
able, the failure rate dramatically decreased, from 7.6% (failure rate observed in the first period
of treatment, 2015) to 1.4% in the second period (end of 2015–2016). These findings are partic-
ularly relevant given the fact that in Italy access to DAA treatment was initially restricted to
patients with a clinical or elastography diagnosis of liver cirrhosis and to patients with
advanced liver fibrosis.
Regarding retreatment with a second DAA regimen, all patients who failed to the first DAA
treatment were eligible to retreatment. Most of these patients (106 of 139: 77%) were previously
treated with SOF+RBV or SOF/SIM. During the study period, 72 (67.3%) of them received a
second treatment by adding a second DAA (when SOF+RBV was used in the first treatment) or
a regimen containing an NS5A inhibitor, in accordance with the European Association for the
Study of the Liver guidelines. Of the remaining 67 not retreated patients, 38 (35.8%) treated
with a first line SOF/RBV or SOF/SIM (30 in Child Pugh Class A and 5 in Child Pugh B class)
were awaiting second treatment access (median time from failure to the end of the study 5
months: range 2–8 months) whereas 29 (87.9%) treated with a first line NS5A inhibitor were
waiting for the resistance test or more appropriate future DAA regimens. Considering the pres-
ence of advanced fibrosis in most of the patients, prompt re-treatment to halt viral replication
and disease progression would be more than desirable. Thus to guarantee the most appropriate
therapeutic option considering the only available regimens reported in this study, a resistance
test could be performed to minimize the risk of a second treatment failure.
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The most important results of this study deal with the clinical events for who first failed to
eradicate HCV, from baseline to treatment outcome, which were prospectively monitored
both after the first DAA course and following retreatment. In this regard, we hypothesized that
the deterioration of the Child-Pugh class as well as the first appearance of signs of liver decom-
pensation, such as ascites and/or encephalopathy, and liver related deaths could be associated
with continuous HCV replication and therefore liver necro-inflammatory activity [23–25]. As
previously reported, improvement in important clinical outcomes has been observed in cir-
rhotic patients following SVR [7,26]. In our study, following SVR12 after retreatment, an
improvement in Child-Pugh class was observed in 17 (23.6%) of the patients with decompen-
sated liver disease whereas in part of patients for whom the Child-Pugh class did not change
(i.e., class A patients) and electrography data were available, liver stiffness significantly
improved following successful retreatment (data not shown).
The results of this ongoing study on patients who obtained the SVR12 in PITER cohort, fur-
ther confirms the benefit of obtaining SVR in clinical outcomes even in patients who had
cirrhosis.
However, as previously reported in patients with HCV-induced cirrhosis and SVR, although
there is a reduction in risk in patients with cirrhosis, particularly in those with advanced liver
cirrhosis, the progression of liver disease may continue regardless of viral eradication [27–33].
Our data confirm these findings, showing that in a small proportion of patients, liver disease
stage deteriorated, despite the patients’ having achieved SVR, and that only a slight improve-
ment in ascites or encephalopathy was observed in some patients. Furthermore, for 5 (6.9%) of
the patients who failed the first line DAA therapy, OLT was deemed necessary and 2 (2.8%) of
the patients died despite having achieved viral eradication after retreatment. These findings sug-
gest that we should proceed with caution, given that in some patients with advanced liver dis-
ease, liver function may not improve, or it may even worsen, regardless of viral eradication.
We observed de novo HCC incidence in 13.8% of the patients who experienced treatment
failure. Several concerns have been recently raised on the potential role of antiviral therapy in
the higher occurrence of HCC in DAA-treated patients with cirrhosis [25,34]. Moreover, a
higher incidence of HCC was reported in patients who experienced treatment failure, com-
pared to those who achieved SVR in the same stage of liver disease in a prospective study
[35,36]. The frequency of de novo HCC was relatively high in this study, and a potential role of
HCC in decreasing the chance of successful DAA treatment, which has been recently reported,
cannot be ruled out [25,34,35,37,38]. To this regard, we should stress that the majority of
HCCs (70%) were observed within 6 months of the end of treatment; it is thus reasonable that
these cancers were sub-clinically present before DAA treatment.
In conclusion, the results of this study, which are based on data collected in a real-life set-
ting, suggest that the failure rate following the first DAA regimen is similar to or lower than
the rates reported in clinical trials. This finding is particularly noteworthy given the fact that
the majority of patients who failed to achieve the SVR12 were treated with DAA regimens that
are now considered as inappropriate taking into account also the severity of liver disease of the
treated population. Although treatment failure is uncommon, its clinical consequences are
important. Interim results showed that patients who experienced treatment failure had a wors-
ening of liver disease, which was nevertheless “rescued” by successful retreatment in the major-
ity of cases. This notwithstanding, some patients had no improvement in liver function
following successful retreatment, which suggests that some caution should be taken in evaluat-
ing the potential clinical outcome of viral eradication in patients with advanced liver disease.
Thus it must be stressed that “curing” HCV might not be the ultimate goal in patients with
severe liver disease, although this study was not specifically designed to identify patients who
do not benefit from viral clearance.
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